Cybin D/B/A Helus Pharma (HELP) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Cybin D/B/A Helus Pharma (HELP) closed at USD 10.38 on 2026-10-14, a change of +45.2 % over the past year, with a market capitalization of USD 807.42M.
Cybin D/B/A Helus Pharma recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 10.38 |
| 2026-10-13 | 10.50 |
| 2026-10-12 | 11.03 |
| 2026-10-09 | 11.80 |
| 2026-10-08 | 10.72 |
| 2026-10-07 | 10.51 |
| 2026-10-06 | 10.76 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Cybin D/B/A Helus Pharma key figures
- Previous close
- USD 10.38 (2026-10-14)
- 1-year change
- +45.2 %
- Market cap
- USD 807.42M
- Enterprise value
- USD 640.95M
- P/E ratio (trailing)
- -2.53
- P/E ratio (forward)
- -6.18
- EPS (trailing)
- -4.37
- EPS (forward)
- -1.79
- PEG ratio
- n/a
- Price to book
- 2.83
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 2.02
- Employees
- 100
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Cybin D/B/A Helus Pharma
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Cybin D/B/A Helus Pharma and compare it with other stocks.
Analyze HELPAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Cybin D/B/A Helus Pharma shares.